Item 5. Other Information
1K characters. Original on sec.gov ·
Item 5. Other Information
Other Information
Rule 10b5-1 Plan Adoptions and Modifications
During the three months ended September 30, 2023, Deborah L. Weitzman, Chief Executive Officer, Pharmaceutical Segment, adopted a Rule 10b5-1 sales plan. Adopted on August 28, 2023, Ms. Weitzman's plan provides for the sale of up to 9,000 common shares and the exercise of vested stock options and the associated sale of up to 27,642 common shares through November 15, 2024. The plan was adopted during an open trading window and is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act and our policies regarding insider transactions. Except for the adoption of Ms. Weitzman’s plan, no other director or officer adopted, modified or terminated a "Rule 10b5-1 trading arrangement" or "non-Rule10b5-1 trading arrangement" as each term is defined in Section 408(a) of Regulation S-K under the Exchange Act.
| Cardinal Health | Q1 Fiscal 2024 Form 10-Q | 20 |
Previous: Item 1A. Risk Factors · Next: Item 1. Financial Statements